Patents by Inventor José Saldanha

José Saldanha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment and Prophylaxis of Amyloidosis
    Publication number: 20210008185
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Application
    Filed: May 20, 2020
    Publication date: January 14, 2021
    Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: Dale B. SCHENK, Peter A. SEUBERT, Jonathan WALL, José SALDANHA
  • Humanized antibodies that recognize alpha-synuclein
    Patent number: 10875909
    Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: December 29, 2020
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Jose Saldanha, Tarlochan S. Nijjar
  • Humanized Antibodies That Recognize Alpha-Synuclein
    Publication number: 20200277362
    Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.
    Type: Application
    Filed: February 19, 2020
    Publication date: September 3, 2020
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Jose Saldanha, Tarlochan S. Nijjar
  • Humanized antibodies that recognize alpha-synuclein
    Patent number: 10597441
    Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: March 24, 2020
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Jose Saldanha, Tarlochan S. Nijjar
  • Humanized Antibodies That Recognize Alpha-Synuclein
    Publication number: 20190153080
    Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.
    Type: Application
    Filed: September 27, 2018
    Publication date: May 23, 2019
    Inventors: Jose Saldanha, Tarlochan S. Nijjar
  • TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS
    Publication number: 20180360934
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Application
    Filed: May 29, 2018
    Publication date: December 20, 2018
    Applicants: PROTHENA THERAPEUTICS LIMITED, UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: DALE B. SCHENK, PETER A. SEUBERT, JONATHAN WALL, JOSÉ SALDANHA
  • Humanized antibodies that recognize alpha-synuclein
    Patent number: 10118960
    Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: November 6, 2018
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Jose Saldanha, Tarlochan S. Nijjar
  • Humanized Antibodies That Recognize Alpha-Synuclein
    Publication number: 20180016329
    Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.
    Type: Application
    Filed: May 4, 2017
    Publication date: January 18, 2018
    Inventors: Jose Saldanha, Tarlochan S. Nijjar
  • Humanized antibodies that recognize alpha-synuclein
    Patent number: 9670273
    Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: June 6, 2017
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Jose Saldanha, Tarlochan S. Nijjar
  • TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS
    Publication number: 20170081396
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Application
    Filed: May 20, 2016
    Publication date: March 23, 2017
    Applicants: PROTHENA THERAPEUTICS LIMITED, UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: DALE B. SCHENK, PETER A. SEUBERT, JONATHAN WALL, JOSÉ SALDANHA
  • Humanized Antibodies That Recognize Alpha-Synuclein
    Publication number: 20160251416
    Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.
    Type: Application
    Filed: November 10, 2015
    Publication date: September 1, 2016
    Inventors: Jose Saldanha, Tarlochan S. Nijjar
  • Humanized antibodies that recognize alpha-synuclein
    Patent number: 9234031
    Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: January 12, 2016
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Jose Saldanha, Tarlochan S. Nijjar
  • Humanized antibodies that recognize alpha-synuclein
    Patent number: 9217030
    Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: December 22, 2015
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Jose Saldanha, Tarlochan S. Nijjar
  • TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS
    Publication number: 20150158937
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Application
    Filed: June 25, 2014
    Publication date: June 11, 2015
    Applicant: ONCLAVE THERAPEUTICS LIMITED
    Inventors: Dale B. SCHENK, Peter A. SEUBERT, José SALDANHA
  • THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN
    Publication number: 20150064177
    Abstract: The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated lung injury.
    Type: Application
    Filed: August 27, 2014
    Publication date: March 5, 2015
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Mary M. BENDIG, Olivier J. LEGER, Jose SALDANHA, Tarran S. JONES, Ted A. Yednock
  • Humanized Antibodies That Recognize Alpha-Synuclein
    Publication number: 20150056187
    Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.
    Type: Application
    Filed: July 24, 2014
    Publication date: February 26, 2015
    Applicant: NEOTOPE BIOSCIENCES LIMITED
    Inventors: Jose Saldanha, Tarlochan S. Nijjar
  • Humanized Antibodies That Recognize Alpha-Synuclein
    Publication number: 20150024433
    Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.
    Type: Application
    Filed: July 24, 2014
    Publication date: January 22, 2015
    Applicant: NEOTOPE BIOSCIENCES LIMITED
    Inventors: Jose Saldanha, Tarlochan S. Nijjar
  • Humanized antibodies that recognize alpha-synuclein
    Patent number: 8790644
    Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: July 29, 2014
    Assignee: Neotope Biosciences Limited
    Inventors: Jose Saldanha, Tarlochan S. Nijjar
  • Treatment and prophylaxis of amyloidosis
    Patent number: 8791243
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Grant
    Filed: December 29, 2008
    Date of Patent: July 29, 2014
    Assignee: Onclave Therapeutics Limited
    Inventors: Dale B. Schenk, Peter A. Seubert, Jonathan Wall, Jose Saldanha
  • TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS
    Publication number: 20140134103
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Application
    Filed: December 6, 2013
    Publication date: May 15, 2014
    Applicants: University of Tennessee Research Foundation, Elan Pharmaceuticals, Inc.
    Inventors: Dale B. SCHENK, Peter A. Seubert, Jonathan Wall, José Saldanha